Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III extension study of lonoctocog alfa in severe hemophilia A
2013-003262-13Phase 3Completed
- Sponsor
- CSL Limited
- Start
- May 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lonoctocog alfa in hemophilia A, sponsored by CSL Limited. Primary endpoint: Incidence rate of inhibitor formation to factor VIII over 100 exposure days. Started May 2014; status: completed.
02
Drugs
lonoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2013-003262-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003262-13.